drugset
Drugs / FF-10501-01
last change Apr 2020 re-read 3 minutes ago

FF-10501-01

Developed for
myelodysplastic syndrome · acute myeloid leukemia · chronic myelomonocytic leukemia
Investigated by
Fujifilm Pharmaceuticals U.S.A., Inc.

Trials 2

today NCT03486353 · Ph 2 NCT02193958 · Ph 1/2
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT02193958 Jul 2014 → Aug 2019 acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome Fujifilm Pharmaceuticals U.S.A., Inc. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03486353 Oct 2019 myelodysplastic syndrome Fujifilm Pharmaceuticals U.S.A., Inc. Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as FF-10501-01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03486353 ↗
1

NCT02193958 ↗
Action Inhibit “FF-10501-01 potently inhibits inosine-5-monophosphate dehydrogenase (IMPDH)” PMID 32264726 ↗ Apr 2020
Route Oral “Subjects will receive FF-10501-01 orally” NCT02193958 ↗